Achaogen's lead antibiotic succeeds in two key studies

(Reuters) - Achaogen Inc said its lead experimental drug, plazomicin, was as effective as the broad spectrum antibiotic, meropenem, in a late-stage trial involving patients with complicated urinary tract infections and acute pyelonephritis.